Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs by Pascual, Aurélie et al.
RESEARCH Open Access
Use of the atmospheric generators for
capnophilic bacteria Genbag-CO2 for the
evaluation of in vitro Plasmodium falciparum
susceptibility to standard anti-malarial drugs
Aurélie Pascual
1,2, Leonardo K Basco
2, Eric Baret
1,2, Rémy Amalvict
1,2, Dominique Travers
1,2,
Christophe Rogier
1,2, Bruno Pradines
1,2,3*
Abstract
Background: The aim of this study was to evaluate the cultivation system in which the proper atmospheric
conditions for growing Plasmodium falciparum parasites were maintained in a sealed bag. The Genbag
® system
associated with the atmospheric generators for capnophilic bacteria Genbag CO2
® was used for in vitro
susceptibility test of nine standard anti-malarial drugs and compared to standard incubator conditions.
Methods: The susceptibility of 36 pre-identified parasite strains from a wide panel of countries was assessed for
nine standard anti-malarial drugs (chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine,
dihydroartemisinin, atovaquone and pyrimethamine) by the standard 42-hour
3H-hypoxanthine uptake inhibition
method using the Genbag CO2
® system and compared to controlled incubator conditions (5% CO2 and 10% O2).
Results: The counts per minute values in the control wells in incubator atmospheric conditions (5% CO2 and 10%
O2) were significantly higher than those of Genbag
® conditions (2738 cpm vs 2282 cpm, p < 0.0001). The
geometric mean IC50 estimated under the incubator atmospheric conditions was significantly lower for atovaquone
(1.2 vs 2.1 nM, p = 0.0011) and higher for the quinolines: chloroquine (127 vs 94 nM, p < 0.0001), quinine (580 vs
439 nM, p < 0.0001), monodesethylamodiaquine (41.4 vs 31.8 nM, p < 0.0001), mefloquine (57.5 vs 49.7 nM, p =
0.0011) and lumefantrine (23.8 vs 21.2 nM, p = 0.0044). There was no significant difference of IC50 between the 2
conditions for dihydroartemisinin, doxycycline and pyrimethamine.
To reduce this difference in term of anti-malarial susceptibility, a specific cut-off was estimated for each drug under
Genbag
® conditions by regression. The cut-off was estimated at 77 nM for chloroquine (vs 100 nM in 10% O2), 611
nM for quinine (vs 800 nM), 30 nM for mefloquine (vs 30 nM), 61 nM for monodesethylamodiaquine (vs 80 nM)
and 1729 nM for pyrimethamine (vs 2000 nM).
Conclusions: The atmospheric generators for capnophilic bacteria Genbag CO2
® is an appropriate technology that
can be transferred to the field for epidemiological surveys of drug-resistant malaria. The present data suggest the
importance of the gas mixture on in vitro microtest results for anti-malarial drugs and the importance of
determining the microtest conditions before comparing and analysing the data from different laboratories and
concluding on malaria resistance.
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Over the past 20 years, many strains of Plasmodium falci-
parum have become resistant to chloroquine and other
anti-malarial drugs [1]. Since 2001, more than 60 coun-
tries have officially adopted artemisinin-based combina-
tion therapies (ACTs) for the treatment of falciparum
malaria [2,3]. However, clinical failures or at least longer
parasite clearance times with ACT have been described
in Cambodia [4-7]. The emergence and spread of resis-
tance to most of the anti-malarial drugs require intensive
research into identifying molecular markers of resistance,
as well as implementing in vitro and in vivo surveillance
programmes, such as those supported by the Worldwide
Antimalarial Resistance Network [8,9].
There are basically three approaches to assess anti-
malarial drug susceptibility of P. falciparum: assessment
of therapeutic efficacy standardized by the World Health
Organization (WHO) [10], in vitro assays and molecular
markers of resistance.
In a number of laboratories surveying anti-malarial
drug resistance, in vitro tests are performed using the
uptake of a radiolabelled nucleic acid precursor [
3H]-
hypoxanthine as a marker of parasite growth [11]. Other
non-radioactive methods can be used: the WHO schi-
zont maturation test by optical microscopy (Mark III)
with pre-dosed plates [12], which was based on the
methods of Rieckmann et al [13] and Wernsdorfer [14],
a flow cytometric analysis of propidium iodide incor-
poration into parasite, which permits a stage-specific
evaluation of anti-malarial compounds [15], a fluores-
cent-based technique that uses SYBR green I which
binds to DNA [16,17], and colorimetric or enzyme-
linked immunosorbent assays (ELISA) to measure histi-
dine-rich protein II (HRP2) [18,19] or plasmodial lactate
dehydrogenase enzyme (pLDH) [20,21].
Many factors induce high variations in P. falciparum
growth and 50% inhibitory concentration (IC50)v a l u e sa n d
influence the results of the chemosusceptibility tests [22],
such as culture medium, initial parasitaemia, haematocrit,
incubation time, time point when [
3H]-hypoxanthine is
added, use of serum substitutes, storage conditions of
sample, delay before cultivation of samples and atmo-
sphere (gas mixtures).
Laboratories using isotopic microtest to monitor drug
resistance work at different oxygen tensions: 3% O2 [15],
5% O2 [18,19], 10% O2 [23,24], in candle jars [20,25]
(which corresponds to approximately 17-18% O2)a n d
>20% O2 [21,22] (in CO2 incubators). WHO recom-
mends the use of a candle jar in their in vitro microtests
(Mark III). Despite the varying culture conditions, many
laboratories have adopted the same threshold for the
resistance to anti-malarial compounds under different
oxygen tensions. For example, our previous study has
shown that the chloroquine IC50 values at 10% O2 were
significantly higher than those at 21% O2 [26]. Neverthe-
less, it seems that O2 concentrations between 1% and
17.5% do not affect the IC50 values of quinoline-contain-
ing anti-malarial drugs [27-29]. In contrast, the in vitro
anti-malarial activity of some antibiotics was dependent
on the O2 concentration [27].
The aim of this study was to evaluate a cultivation
system in which the proper conditions of atmosphere
for growing P. falciparum parasites were maintained in
an air-tight sealed bag. The Genbag
® system was initi-
ally designed as atmospheric generators for capnophilic
bacteria. Genbag CO2
® (BioMérieux;Marcy l’Etoile,
France) was used for in vitro susceptibility test of nine
standard anti-malarial drugs, and the IC50sw e r ec o m -
pared to those obtained with controlled incubator con-
ditions (5% CO2, 10% O2 and 85% N2).
Methods
Strains of P. falciparum
A total of 36 pre-identified parasite strains (well-charac-
terized laboratory strains or strains obtained from iso-
lates after growth in culture for an extended period of
time) from a wide panel of countries were maintained in
culture in RPMI 1640 (Invitrogen, Paisley, United King-
dom), supplemented with 10% human serum (Abcys
S.A., Paris, France) and buffered with 25 mM HEPES
and 25 mM NaHCO3. Parasites were grown in type A
+
human red blood cells under controlled atmospheric
conditions that consisted of 10% O2,5 %C O 2 and 85%
N2 at 37°C with a relative humidity of 95%. All strains
were synchronized twice with sorbitol before use [30].
Clonality was verified using PCR genotyping of poly-
morphic genetic markers msp1, msp2, and microsatellite
loci [31,32]. Chloroquine-susceptible 3D7 clone and
chloroquine-resistant W2 clone (MR4 Resource Center)
were cultivated in the same conditions and assessed for
drug susceptibility in 4 independent experiments.
Drugs
Chloroquine, quinine, dihydroartemisinin, pyrimetha-
mine and doxycycline were purchased from Sigma
(Saint Louis, MO). Monodesethylamodiaquine was
obtained from the WHO (Geneva, Switzerland). Meflo-
quine was obtained from Roche (Paris, France). Lume-
f a n t r i n ew a sp r o v i d e db yN o v a r t i sP h a r m a( B a s e l ,
Switzerland), and atovaquone was from GlaxoSmithK-
line (Evreux, France). Chloroquine and pyrimethamine
were dissolved and diluted in water to obtain final con-
centrations ranging from 5 to 3,200 nM for chloroquine
and 5 to 40,000 nM for pyrimethamine. Quinine, mono-
desethylamodiaquine, mefloquine, dihydroartemisinin,
atovaquone and doxycycline were first dissolved in
methanol and then diluted in water to obtain final con-
centrations ranging from 5 to 3,200 nM for quinine,
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400 nM for mefloquine, 0.1 to 100 nM for dihydroarte-
misinin, 0.3 to 100 nM for atovaquone and 0.1 to
502 μM for doxycycline. Lumefantrine was dissolved
and diluted in ethanol to obtain final concentrations
ranging from 0.5 to 310 nM.
In vitro assay
For in vitro isotopic microtests, 200 μL/well of a suspen-
sion of synchronous parasitized red blood cells (final
parasitaemia, 0.5%; final haematocrit, 1.5%) was distribu-
ted in 96-well plates predosed with anti-malarial drugs.
Parasite growth was assessed by adding 1 μCi of tritiated
hypoxanthine with a specific activity of 14.1 Ci/mmol
(Perkin-Elmer, Courtaboeuf, France) to each well at
time zero. The plates were incubated for 42 h at 37°C in
controlled atmospheric conditions in incubator (5%
CO2, 10% O2 and 85% N2) and Genbag
® with the atmo-
spheric generators for capnophilic bacteria Genbag
CO2
® (two plates per sealed bag) (Figure 1). Immedi-
ately after incubation, plates were frozen and then
thawed to lyse the erythrocytes. The contents of each
well were collected on standard filter microplates (Uni-
filter GF/B; Perkin-Elmer) and washed using a cell har-
vester (Filter-Mate Cell Harvester; Perkin-Elmer). The
filter microplates were dried, and 25 μL of scintillation
cocktail (Microscint O; Perkin-Elmer) were placed in
each well. The radioactivity incorporated into the
nucleotides of the parasites was measured with a scintil-
lation counter (Top Count; Perkin-Elmer).
The drug concentration that inhibits 50% of parasite
growth (IC50) was designated as the concentration at
which the tritiated hypoxanthine incorporation reached
50% of the total incorporation by the parasites in the
drug-free control wells. The IC50 value was determined
by non-linear regression analysis of log-based dose-
response curves (Riasmart, Packard, Meriden, USA).
Statistical analysis
Count per minute (cpm) and IC50 were expressed as
geometric means and 95% confidence intervals. The dif-
ferences between the data observed in the incubator and
Genbag
® were analysed by a paired t-test. The correla-
tion between the responses under two incubation condi-
tions for each anti-malarial drug was estimated by the
Pearson correlation coefficient R. The same analyses
were performed on IC50 strains/IC50 3D7 or IC50
strains/IC50 W2 ratios calculated for each anti-malarial
drug under the two conditions.
Results
A total of 1,098 drug-free control wells were analysed
for each experimental condition. A significant difference
was observed in the tritiated hypoxanthine uptake
between the two conditions with 36 strains of P. falci-
parum (Table 1). The mean cpm values in the control
wells under the controlled incubator conditions (5%
CO2 and 10% O2) were significantly higher than those
under Genbag
® conditions (2738 vs 2282 cpm, p value <
0.0001).
Compared to Genbag
® conditions (5% CO2 and 15%
O2), the geometric mean IC50 estimated under the incu-
bator atmospheric conditions (5% CO2 and 10% O2) was
significantly lower for atovaquone (1.2 vs 2.1 nM, p =
0.0011) and higher for the quinolines: chloroquine (127
vs 94 nM, p < 0.0001), quinine (580 vs 439 nM, p <
0.0001), monodesethylamodiaquine (41.4 vs 31.8 nM,
p < 0.0001), mefloquine (57.5 vs 49.7 nM, p = 0.0011)
and lumefantrine (23.8 vs 21.2 nM, p = 0.0044) (Table 1).
There was no significant difference of IC50 between the
two conditions for dihydroartemisinin, doxycycline and
pyrimethamine.
The cpm and IC50 values for each anti-malarial drug
were highly and significantly correlated between the two
conditions (Figure 2, 3 and 4).
Based on the thresholds of decreased susceptibility
defined for the incubator atmospheric conditions (5%
CO2 and 10% O2), the following discrepancies were
observed: one of 21 strains (5%) with IC50 >100 nM for
chloroquine [33] was <100 nM under Genbag
® condi-
tions; seven of 20 strains (35%) with IC50 >800 nM for
quinine [34] was <800 nM under Genbag
® conditions;
t w oo f2 0s t r a i n s( 1 0 % )w i t hI C 50 >30 nM for meflo-
quine [35] was <30 nM under Genbag
® conditions; four
of 10 strains (40%) with IC50 >80 nM for monodesethy-
lamodiaquine [36] was <80 nM under Genbag
® condi-
tions; and none of the 13 strains with IC50 >2,000 nM
for pyrimethamine [37] was < 2,000 nM under Genbag
®
conditions.
Figure 1 The Genbag
® system associated with the atmospheric
generators for capnophilic bacteria Genbag CO2
® with 2 plates
in the specific sealed bag (picture P Millileri).
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ceptibility, a specific cut-off was estimated for each drug
under Genbag
® conditions by regression. The cut-off
was estimated at 77 nM for chloroquine (vs 100 nM in
10% O2), 611 nM for quinine (vs 800 nM), 30 nM for
mefloquine (vs 30 nM), 61 nM for monodesethylamo-
diaquine (vs 80 nM) and 1729 nM for pyrimethamine
(vs 2,000 nM). The cut-off was not re-estimated for
drugs for which all the CI50 values were below the cut-
off under controlled incubation conditions. For these
drugs, median values were estimated: 2.9 nM for atova-
quone (vs 2.5 nM in 10% O2), 26 nM for lumefantrine
(vs 30 nM), 3 nM for dihydroartemisinin (vs 3.0 nM)
and 15 μM for doxycycline (vs 15 μM).
The geometric mean ratio based on the chloroquine-
susceptible reference clone 3D7 (strain IC50/3D7 IC50)
obtained under the incubator atmospheric conditions
(5% CO2 and 10% O2) was significantly higher for chlor-
oquine (p < 0.0001), lumefantrine (p = 0.0119), and
dihydroartemisinin (p = 0.0006), but the ratio was signif-
icantly lower for mefloquine (p < 0.0001) and doxycy-
cline (p = 0.0002) (Table 2). The geometric mean ratio
based on the chloroquine-resistant reference clone W2
(strain IC50/W2 IC50) obtained under the incubator
atmospheric conditions (5% CO2 and 10% O2)w a ss i g -
nificantly higher for chloroquine (p = 0.0014), quinine
(p = 0.0006), monodesethylamodiaquine (p < 0.0001),
lumefantrine (p < 0.0001), pyrimethamine (p = 0.0026)
and was significantly lower for dihydroartemisinin (p <
0.0001) and doxycycline (p = 0.0159) (Table 3).
Discussion
The first works that assessed oxygen effects on P. falci-
parum asynchronous cultures had shown that microaer-
ophilic environment allowed an optimal development of
parasites [38]. Parasite growth failed under strict anaero-
bic conditions. Plasmodium falciparum possesses a
functional mitochondrial respiratory chain with oxygen
consumption [39]. It has been shown that there is some
protector effect of CO2 at high oxygen concentration
[38] through the medium pH, the stability (between 7.2
and 7.45) of which is required for parasite growth [40].
The standard medium RPMI 1640, buffered with
25 mM HEPES and 25 mM NaHCO3, was optimized to
maintain the pH within the physiological range in an
atmosphere containing 5% CO2. Any modification of the
CO2 concentration alters the pH of the medium, which
in turn can influence the IC50 values of pH-dependent
drugs, such as quinolines, but not of those that are
pH-independent, such as pyrimethamine. Despite similar
growth and tritium-labelled hypoxanthine incorporation
rates in drug-free control wells, Shenyi He et al showed
that increasing the CO2 concentration from 2.7% to 7%
(with a constant 5% O2)r e s u l t e di ns i g n i f i c a n t l yh i g h e r
Table 1 In vitro activity of chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine,
pyrimethamine, atovaquone, dihydroartemisinin and doxycycline against 36 strains of Plasmodium falciparum under
controlled incubator conditions (10% O2) and Genbag
® conditions (15% O2)
Compound O2 %I C 50 t-test p-value
Geometric mean 95%CI Min Max
Chloroquine 10 127 nM 77-211 8 1032 <0.0001
15 94 nM 61-146 12 751
Quinine 10 580 nM 451-745 153 1752 <0.0001
15 439 nM 336-573 96 1288
Mefloquine 10 57.5 nM 50.7-65.3 30.8 131.0 0.0011
15 49.7 nM 44.0-46.3 26.4 113.0
Monodesethylamodiaquine 10 41.4 nM 28.8-59.6 4.7 379 <0.0001
15 31.8 nM 21.8646.2 4.0 357
Lumefantrine 10 23.8 nM 19.6628.8 7.1 65.0 0.0044
15 21.2 nM 17.5-25.7 7.2 72
Pyrimethamine 10 273 nM 88-852 10 17025 0.0902
15 222 nM 67-735 10 14938
Atovaquone 10 1.2 nM 0.8-1.8 0.1 7.3 0.0011
15 2.1 nM 1.6-2.8 0.2 11.7
Dihydroartemisinin 10 2.4 nM 2.0-2.9 1.2 10.8 0.4088
15 2.4 nM 1.9-2.9 1.0 14.3
Doxycycline 10 10.9 μM 9.8-12.1 7.6 26.0 0.6771
15 10.8 μM 9.5-12.2 6.3 24.5
cpm 10 2738 2628-2852 671 17845 <0.0001
15 2282 2189-2379 623 12726
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Page 4 of 10chloroquine IC50 values [29]. The chloroquine-resistant
K1 strain showed nine-fold greater chloroquine IC50
when the CO2 concentration was increased from 2.7 to
7% [29].
The atmospheric generators for capnophilic bacteria
Genbag CO2
® evaluated in this study release about 5%
CO2 and reduce to 15% O2 in 30 min, according to the
manufacturer’s specifications (http://www.biomerieux-
diagnostics.com/servlet/srt/bio/clinical-diagnostics/dyn-
Page?doc=CNL_PRD_CPL_G_PRD_CLN_62). The stated
conditions are maintained at least for 48 h. In this con-
text, it seems that the significant differences in drug
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Figure 2 Correlation between log IC50 values of chloroquine, quinine or mefloquine, against 36 strains of Plasmodium falciparum
under controlled incubator conditions (10% O2) and Genbag
® conditions (15% O2).
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Page 5 of 10IC50 values and growth level (cpm) between the two
conditions, the incubator atmospheric conditions (5%
CO2 and 10% O2) and the Genbag
® conditions (5% CO2
and 15% O2), are due to the difference in O2
concentration.
The IC50 values of quinoline drugs, such as chloro-
quine, quinine, monodesethylamodiaquine, mefloquine
and lumefantrine were significantly lower at 15% O2
(Genbag CO2
®) than those at 10% O2 (the incubator
atmospheric conditions). This is in agreement with the
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Figure 3 Correlation between log IC50 values of monodesethylamodiaquine, lumefantrine or pyrimethamine against 36 strains of
Plasmodium falciparum under controlled incubator conditions (10% O2) and Genbag
® conditions (15% O2).
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Page 6 of 10previous results that showed in 136 P. falciparum fresh
isolates from Comoros that the chloroquine IC50 values
at 10% O2 were significantly higher than those at 21%
O2, with the means of 173.5 nM and 121.5 nM, respec-
tively [26]. Of particular interest among the 63 isolates
that were resistant in vitro to chloroquine (IC50 >100 nM)
at 5% CO2 and 10% O2, was the observation that 17
were susceptible to chloroquine (IC50 < 100 nM) at 21%
O2 [26]. In the present study, only one of 21 strains with
chloroquine IC50 >100 nM at 10% O2 had IC50 < 100 nM
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Figure 4 Correlation between log IC50 values of atovaquone, dihydroartemisinin or doxycycline against 36 strains of Plasmodium
falciparum under controlled incubator conditions (10% O2) and Genbag
® conditions (15% O2).
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Page 7 of 10Table 2 Ratio based on the chloroquine-susceptible reference clone 3D7 (strain IC50/3D7 IC50) of chloroquine, quinine,
mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and
doxycycline against 36 strains of Plasmodium falciparum under controlled incubator conditions (10% O2) and Genbag
®
conditions (15% O2)
Compound O2 %I C 50 /3D7 IC50 t-test p-value
Geometric mean 95%CI Min Max
Chloroquine 10 6.88 4.15-11.41 0.40 55.80 <0.0001
15 4.80 3.09-7.45 0.60 38.30
Quinine 10 2.44 1.90-3.13 0.65 7.39 0.2418
15 2.63 2.04-3.40 0.66 7.24
Mefloquine 10 0.72 0.63-0.82 0.39 1.64 <0.0001
15 0.91 0.81-1.03 0.49 2.089
Monodesethylamodiaquine 10 2.59 1.80-3.72 0.29 23.69 0.5948
15 2.52 1.73-3.67 0.32 28.33
Lumefantrine 10 0.90 0.74-1.09 0.27 2.45 0.0119
15 0.81 0.67-0.98 0.28 2.76
Pyrimethamine 10 27.31 8.75-85.21 1.00 1703 0.0835
15 18.01 5.51-58.82 1.00 1494
Atovaquone 10 0.88 0.59-1.31 0.07 5.20 0.9187
15 0.89 0.67-1.19 0.08 4.96
Dihydroartemisinin 10 1.53 1.27-1.85 0.74 6.79 0.0006
15 1.31 1.04-1.64 0.54 7.94
Doxycycline 10 1.21 1.09-1.35 0.85 2.90 0.0002
15 1.37 1.21-1.55 0.80 3.11
Table 3 Ratio based on the chloroquine-resistant reference clone W2 (strain IC50/W2 IC50) of chloroquine, quinine,
mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and
doxycycline against 36 strains of Plasmodium falciparum under controlled incubator conditions (10% O2) and Genbag
®
conditions (15% O2)
Compound O2 %I C 50 /W2 IC50 t-test p-value
Geometric mean 95%CI Min Max
Chloroquine 10 0.26 0.16-0.43 0.02 2.12 0.0014
15 0.21 0.14-0.33 0.03 1.71
Quinine 10 0.71 0.56-0.90 0.19 2.04 0.0006
15 0.56 0.43-0.74 0.12 1.65
Mefloquine 10 0.97 0.66-1.42 0.43 1.82 0.6262
15 0.82 0.72-0.92 0.43 1.85
Monodesethylamodiaquine 10 0.49 0.34-0.70 0.06 4.47 <0.0001
15 0.37 0.25-0.54 0.05 4.14
Lumefantrine 10 1.25 1.03-1.52 0.37 3.42 <0.0001
15 0.94 0.78-1.15 0.32 3.21
Pyrimethamine 10 0.03 0.01-0.10 0.001 1.96 0.0026
15 0.02 0.01-0.07 0.0008 1.26
Atovaquone 10 0.65 0.44-0.97 0.05 3.85 0.8646
15 0.67 0.50-0.89 0.06 3.71
Dihydroartemisinin 10 1.06 0.88-1.28 0.51 4.70 <0.0001
15 1.55 1.24-1.94 0.65 9.41
Doxycycline 10 1.16 1.05-1.29 0.81 2.78 0.0159
15 1.25 11.10-1.42 0.73 2.85
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Page 8 of 10at a concentration of 15%. Some studies failed to show
oxygen-dependent effects of chloroquine on P. falciparum
in culture [27-29], but in these experiments less than four
strains were tested. Shenyi He et al reported that the
chloroquine IC50 values determined in a candle jar (2.7%
CO2 and 17.5% O2) were similar to those determined in
an incubator set at 2.7% CO2 and 5% O2 [27]. Lin et al
observed similar chloroquine IC50 values with parasites
incubated in 5% CO2 and 5% or 15% O2 generated by an
AnaeroPack system [29].
In contrast, there was no significant difference of IC50
values between 10% and 15% O2 conditions for doxycy-
cline, dihydroartemisinin and pyrimethamine. Divo et al.
reported that the anti-malarial activity of different
cyclines was O2-dependent and higher at high O2 con-
centrations [27]. Nevertheless, this influence of O2 was
not evident at 48 h but was profound at 96 h. In the
present study, IC50 values were only determined at 42 h.
The class of artemisinins contains an intramolecular
peroxide bridge that is situated in the sesquiterperne
lactone backbone structure. The anti-malarial potency
of artemisinin was enhanced by oxygen and inhibited by
oxygen radical scavengers [41,42]. The contrast between
10 and 15% O2 is probably not high enough to observe
any difference in dihydroartemisinin IC50 values.
Using the threshold values for in vitro resistance
established under the controlled incubator conditions
(5% CO2 and 10% O2), 0 - 40% of discordant results,
depending on the test compounds, was obtained using
the Genbag
® incubation system. The effect of gas mix-
ture on the results of chemosusceptibility assay should
lead different laboratories involved in anti-malarial resis-
tance survey to adapt a resistance threshold for each gas
mixture or to use the same conditions to perform che-
mosusceptibility microtests. The cut-off value was re-
estimated for each drug in Genbag
® conditions. The
cut-off was estimated at 77 nM for chloroquine (vs
100 nM in 10% O2), 611 nM for quinine (vs 800 nM),
30 nM for mefloquine (vs 30 nM), 61 nM for monode-
sethylamodiaquine (vs 80 nM) and 1729 nM for pyri-
methamine (vs 2000 nM).
To reduce the effects of O2 on IC50 values between 10
and 15% O2, the ratios of strain IC50/3D7 IC50 and
strain IC50/W2 IC50 were calculated for each condition.
Nevertheless, the mean ratios were not similar at 10%
and 15% O2 for most anti-malarial drugs, and the results
depended on the reference clone.
Conclusions
The atmospheric generators for capnophilic bacteria
Genbag CO2
® is an appropriate technology that can be
transferred to the field for epidemiological surveys of
drug-resistant malaria. The present data suggest the
importance of the gas mixture on in vitro microtest
results for anti-malarial drugs and the importance of
determining the microtest conditions before comparing
and analysing the data from different laboratories and
concluding on malaria resistance.
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